Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy

摘要

Induction chemotherapy combining anthracyclines and cytarabine has been the cornerstone of therapy for acute myeloid leukaemia (AML) for almost four decades. Several groups, including the Australasian Leukaemia and Lymphoma Group (ALLG), have incorporated high-dose cytarabine (HiDAC) into the initial induction regimen, resulting in very high rates (~80%) of first cycle complete remission (CR) and improved progression-free survival outcomes (Bishop et al, 1996; Bradstock et al, 2005; Braess et al, 2009; Ravandi et al, 2010).